ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Creative Biolabs Shines at the 2024 NIH Research Festival: Showcasing Antibody Solutions

By: Get News
Creative Biolabs made a splash at the 2024 NIH Research Festival, held from Sept. 23 to 25, as they highlighted their groundbreaking work in antibody discovery and development.

New York, USA - October 9, 2024 - The festival, which featured scientific lectures, poster presentations, and workshops, was a vibrant hub of knowledge exchange, and Creative Biolabs took center stage in presenting their cutting-edge antibody solutions.

One of the standout technologies on display was Creative Biolabs' phage display service, which enables the selection of antibodies with high specificity and affinity against a wide range of targets. During the event, the team demonstrated their pipeline from phage construction to screening and their masterpiece in discovering PTM specific antibodies and anti-idiotype antibodies, which gives researchers an edge when looking to discover novel targets in immunotherapy, cancer, and infectious diseases.

Another hot topic during the festival was the growing interest in single domain antibodies — also known as sdAbs. Unlike traditional antibodies, sdAbs are much smaller, making them more versatile and efficient for use in therapeutics, imaging, and diagnostics. Their unique structure allows them to bind to hidden or otherwise hard-to-reach targets, making them highly valuable in cases where conventional antibodies might fall short. At the festival, the Creative Biolabs team demonstrated the versatility of sdAbs, showing how they can be tailored for specific disease targets or used to enhance the efficacy of existing therapies. Attendees were impressed by how these tiny, yet mighty, antibodies are helping to shape the future of targeted therapies.

One of the most exciting aspects of the NIH Research Festival was its focus on next-generation technologies, and Creative Biolabs didn't disappoint in this regard. Their de novo antibody sequencing service was a highlight of their exhibit, offering a revolutionary approach to uncovering the exact amino acid sequence of antibodies. This next-gen sequencing technology is invaluable for researchers looking to decode the precise structures of therapeutic antibodies, particularly when trying to reproduce or improve existing therapies. Creative Biolabs has perfected the method to provide highly accurate results, essential for the development of biosimilars and antibody engineering. Festival-goers were particularly impressed with how this technology can streamline the antibody development process, saving time and resources.

"The NIH Research Festival, with its workshops, poster presentations, and vendor booths, wasn't just an exhibition — it provided a prime opportunity for us to connect with other innovators in the field and inspire the next wave of antibody innovations." One of the delegates said.

Creative Biolabs' contributions to advancing antibody technologies were clear, as they shared insights and connected with fellow scientists, researchers, and industry professionals. Looking to the future, the company remains committed to driving scientific progress by offering flexible, high-quality solutions for antibody development.

Web: https://www.creative-biolabs.com

About

In an industry that's constantly evolving, Creative Biolabs is not just keeping pace — they're setting the standard. Stay tuned as they continue to power the next generation of therapies and push the boundaries of what's possible in antibody research. For the remainder of 2024, a team of dedicated scientists will attend upcoming industry exhibitions to share the latest advancements in biotech with peers.

* October 22, BioPharma Drug Discovery Nexus Conference

* November 4, World ADC San Diego

* December 15, Antibody Engineering & Therapeutics (US) 2024

Media Contact
Company Name: Creative Biolabs
Contact Person: Candy Swift
Email: Send Email
Phone: 1-631-830-6441
Country: United States
Website: https://www.creative-biolabs.com



Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.